CDKN2A and mantle cell lymphoma: ATM-deficient (Granta-519 and Maver-1) and/or CDKN2A-deficient (Granta-519, Maver-1, and Rec-1) MCL cell lines are sensitive to PRMT5 inhibitor GSK3326595 (Fig. 2e).